Ibogaine is an indole alkaloid derived from the bark of the root of the African shrub Tabernanthe iboga. Psychoactive properties of ibogaine have been known for decades. More recently, based on experimental data from animals and anectodal reports in human, it has been found that this drug has anti-addictive effects. Several patents were published between 1969 and 1995. The pharmacology of ibogaine is quite complex, affecting many different neurotransmitter systems simultaneously. However, the pharmacological targets underlying the physiological and psychological actions of ibogaine are not completely understood. Ibogaine is rapidly metabolized in the body in noribogaine. The purpose of this article was to review data from the literature concerning physicochemical properties, bio-analytical methods, and pharmacology of ibogaine; this article will be focused on the use of this drug as anti-addictive agent.
1 Smith CG O’Donnell J . The process of new drug discovery and development.2nd ed.New York: Informa Healthcare; 2006.
2.
2 Atkinson AJ Abernethy D Daniels C Dedrick R Markey S . Principles of clinical pharmacology.2nd ed.Amsterdam: Boston Elsevier/Academic Press; 2007.
3.
3 Jenks CW . Extraction studies of Tabernanthe iboga and Voacanga africana.Nat Prod Lett2002; 16: 71–76.
4.
4 Mash DC Kovera CA Buck BE Norenberg MD Shapshak P Hearn WL . Medication development of ibogaine as a pharmacotherapy for drug dependence.Ann N Y Acad Sci1998; 844: 274–292.
5.
5 Goldblatt A Hootele C Pecher J . The alkaloids of Vocanga Thouarsii Var. Obtusa.Phytochemistry1970; 9: 1293–1298.
6.
6 Andrade MT Pinto AC Rezende CM Carvalho MP Epifanio RA . Indole alkaloids from Tabernaemontana australis (Muëll. Arg) Miers that inhibit acetylcholinesterase enzyme.Bioorg Med Chem2005; 13: 4092–4095.
7.
7 Knox JR Slobbe J . Alkaloids of Ervatamia orientalis. Isolation of alkaloids and structural identification of two dimers.Aust J Chem1975; 28: 1813–1856.
8.
8 Alper KR . Ibogaine: a review. The alkaloids.Academic Press, San Diego, California; 2001.
9.
9 Goutarel R Gollnhofer O Sillans R . Pharmacodynamics and therapeutic applications of Iboga and Ibogaine.Psychedelic Monogr Essays1993; 6: 71–111.
10.
10 Dybowski E . Plant Chemistry Concerning Iboga, its excitement-producing properties, its composition, and the new alkaloid it contains, ibogaine.C R Acad Sci1901; 133: 748.
11.
11 Haller A Heckel E . Sur l'ibogaine, principe actif d'une plante du genre Tabernaemontana, originaire du Congo. Compt Rend Acad Sci1901; 133: 850–853.
12.
12 Lambert M Heckel E . Sur la racine d'Iboga et l'ibogaine. Compt Rend Acad Sci1901; 133: 1236–1238.
13.
13 Taylor WI . Iboga alkaloids. II. The structures of ibogaine, ibogamine and tabernanthine.J Am Chem Soc1957; 79: 3298–3299.
14.
14 Arai G Coppola J Jeffrey GA . The structure of ibogaine.Acta Cryst1960; 13: 553–564.
15.
15 Wenkert E Cochran DW Gottlieb HE Hagaman EW . 13C-NMR. Spectroscopy of naturally occurring substances. XLV. Iboga alkaloids.Helv Chim Acta1976; 59: 2437–2442.
16.
16 Büchi G Coffen DL Kocsis K Sonnet PE Ziegler FE . The total synthesis of iboga alkaloids.J Am Chem Soc1966; 88: 3099–3109.
17.
17 Bocher DP; Naranjo C; . French Special Drug patent No. 138.081;081713m. Inst Class A61k. 1969.
18.
18 Lotsof HS; . Inventor rapid method for interrupting the narcotic addiction syndrome. US patent 4,499,096. 1985.
19.
19 Lotsof HS; . Inventor rapid method for interrupting the cocaine and amphetamine abuse syndrome. US patent 4,587,243. 1986.
20.
20 Lotsof HS; . Inventor rapid method for attenuating the alcohol dependency syndrome. US patent 4,857,523. 1989.
21.
21 Lotsof HS; . Inventor rapid method for interrupting or attenuating poly-drug dependency syndrome. US patent 5,152,994. 1992.
22.
22 Lotsof HS; . Inventor rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome. US patent 5,026,697. 1991.
23.
23 Shulgin A Shulgin A . TIHKAL, The Continuation.Tryptamines I Have Known and Loved. Transform Press, Berkeley, California; 1997.
24.
24 Kontrimavičiūtė V Mathieu O Balas L Escale R Blayac JP Bressolle FMM . Ibogaine and noribogaine: structural analysis and stability studies. Use of LC-MS to determine alkaloid contents from root bark of Tabernanthe iboga.J Liquid Chromatogr Analyt Technol Biomed Life Sci2007; 30: 1077–1092.
25.
25 Taylor WI . The iboga and Vocanca alkaloids. The alkaloids, Chemistry and Physiology.Academic Press, San Diego, California; 1965.
26.
26 Popik P Skolnick P . Pharmacology of ibogaine and ibogaine-related alkaloids. The alkaloids.Academic press; 1999.
27.
27 Kontrimavičiūtė V Larroque M Briedis V Margout D Bressolle F . Quantitation of ibogaine and 12-hydroxy-ibogaine in human plasma by liquid chromatography with fluorimetric detection.J Chromatogr B Analyt Technol Biomed Life Sci2005; 822: 285–293.
28.
28 Dhahir HI Jain NC Forney RB . Methods for the detection and determination of ibogaine in biological materials.J Forensic Sci1971; 16: 103–108.
29.
29 Bertol E Mari F Froldi R . Détection de l'ibogaïne dans les liquides organiques.J Chromatogr1976; 117: 239–241.
30.
30 Dagnino D Schripsema J Peltenburg A Verpoorte R Teunis K . Capillary gas chromatographic analysis of indole alkaloids: investigation of the indole alkaloids present in Tabernaemontana divaricata cell suspension culture.J Nat Prod1991; 54: 1558–1563.
31.
31 Cartoni GP Giarusso A . Gas chromatographic determination of ibogaine in biological fluids.J Chromatogr1972; 71: 154–158.
32.
32 Gallagher CA Hough LB Keefner SM Seyed-Mozaffari A Archer S Glick SD . Identification and quantification of the indole alkaloid ibogaine in biological samples by gas chromatography-mass spectrometry.Biochem Pharmacol1995; 49: 73–79.
33.
33 Ley FR Jeffcoat AR Thomas BF . Determination of ibogaine in plasma by gas chromatography-chemical ionization mass spectrometry.J Chromatogr A1996; 723: 101–109.
34.
34 Hearn WL Pablo J Hime GW Mash DC . Identification and quantitation of ibogaine and an o-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry.J Anal Toxicol1995; 19: 427–434.
35.
35 Alburges ME Foltz RL Moody DE . Determination of ibogaine and 12-hydroxy-ibogamine in plasma by gas chromatography-positive ion chemical ionization-mass spectrometry.J Anal Toxicol1995; 19: 381–386.
36.
36 Bogusz MJ Maier RD Kruger KD Kohls U . Determination of common drugs of abuse in body fluids using one isolation procedure and liquid chromatography-atmospheric-pressure chemical-ionization mass spectrometry.J Anal Toxicol1998; 22:549–558.
37.
37 Kontrimavičiūtė V Breton H Mathieu O Mathieu-Daudé JC Bressolle F . Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root.J Chromatogr B Analyt Technol Biomed Life Sci2006; 843: 131–141.
38.
38 Kontrimavičiūtė V Breton H Barnay F Mathieu-Daudé JC Bressolle F . Liquid chromatography-electrospray mass spectrometry determination of ibogaine and 12-hydroxy-ibogamine in human urine.Chromatographia2006; 63: 533–541.
39.
39 Naranjo C . Psychotherapeutic possibilities of new fantasy-enhancing drugs.Clin Toxicol1969; 2: 209–224.
40.
40 Sheppard SG . A preliminary investigation of ibogaine: case reports and recommendations for further study.J Subst Abuse Treat1994; 11: 379–385.
41.
41 Schechter MD Gordon TL . Comparison of the behavioral effects of ibogaine from three sources: mediation of discriminative activity.Eur J Pharmacol1993; 249: 79–84.
42.
42 Pearl SM Hough LB Boyd DL Glick SD . Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism.Pharmacol Biochem Behav1997; 57: 809–815.
43.
43 Jeffcoat AR; Cook CE; Hill JM; Coleman DP; Pollack GM; . Disposition of [3H] ibogaine in the rat. National Institute on Drug Abuse Research Monograph Series, Bethesda, 1994; 141: 309.
44.
44 Hough LB Bagal AA Glick SD . Pharmacokinetic characterization of the indole alkaloid ibogaine in rats.Methods Find Exp Clin Pharmacol2000; 22: 77–81.
45.
45 Hough LB Pearl SM Glick SD . Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration.Life Sci1996; 58: 119–122.
46.
46 Glick SD Pearl SM Cai J Maisonneuve IM . Ibogaine-like effects of noribogaine in rats.Brain Res1996; 713: 294–297.
47.
47 Zubaran C Shoaib M Stolerman IP Pablo J Mash DC . Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain.Neuropsychopharmacology1999; 21: 119–126.
48.
48 Staley JK Ouyang Q Pablo J Hearn WL Flynn DD Rothman RB . Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.Psychopharmacology1996; 127: 10–18.
49.
49 Mash DC Kovera CA Pablo J Tyndale R Ervin FR Kamlet JD . Ibogaine in the treatment of heroin withdrawal.Alkaloids Chem Biol2001; 56: 155–171.
50.
50 Obach RS Pablo J Mash DC . Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine.Drug Metab Dispos1998; 26: 764–768.
51.
51 Baumann MH Rothman RB Pablo J Mash DC . In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogaine (noribogaine) in rats.J Pharmacol Exp Ther2001; 297: 531–539.
52.
52 Zubaran C . Ibogaine and noribogaine: comparing parent compound to metabolite.CNS Drug Reviews2000; 6: 219–240.
53.
53 Mash DC Staley JK Baumann MH Rothman RB Hearn WL . Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin.Life Sci1995; 57: 45–50.
54.
54 Baumann MH Pablo J Ali SF Rothman RB Mash DC . Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine.Alkaloids2001; 56: 79–113.
55.
55 Baumann MH Pablo J Ali SF Rothman RB Mash DC . Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine.Ann NY Acad Sci2000; 914: 354–368.
56.
56 Mash DC Kovera CA Pablo J Tyndale R Ervin FR Williams IC . Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.Ann N Y Acad Sci2000; 914: 394–401.
57.
57 Pablo JP Mash DC . Noribogaine stimulates naloxone-sensitive [35S] GTPgammaS binding.Neuroreport1998; 9: 109–114.
58.
58 Mash DC Kovera CA Buck BE Norenberg MD Shapshak P Hearn WL . Medication development of ibogaine as a pharmacotherapy for drug dependence.Ann NY Acad Sci1998; 844: 274–292.
59.
59 Glick SD Maisonneuve IS . Mechanisms of antiaddictive actions of ibogaine.Ann N Y Acad Sci1998; 844: 214–226.
60.
60 Rabin RA Winter JC . Effects of ibogaine and noribogaine on phosphoinositide hydrolysis.Brain Res1996; 731: 226–229.
61.
61 Rabin RA Winter JC . Ibogaine and noribogaine potentiate the inhibition of adenylyl cyclase activity by opioid and 5-HT receptors.Eur J Pharmacol1996; 316: 343–348.
62.
62 Paškulin R Jamnik P Živin M Raspor P Štrukelj B . Ibogaine effects brain energy metabolism.Eur J Pharmacol2006; 552: 11–14.
63.
63 He DY McGough NN Ravindranathan A Jeanblanc J Logrip ML Phamluong K . Glial cell line–derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine gains alcohol consumption.J Neurosci2005; 25: 619–628.
64.
64 He DY Ron D . Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine.FASEB J2006; 20: 2420–2422.
65.
65 Gonzalez G Oliveto A Kosten TR . Treatment of heroin (diamorphine) addiction: current approaches and future prospects.Drugs2002; 62: 1331–1343.
66.
66 Gorelick DA Gardner EL Xi ZX . Agents in development for the management of cocaine abuse.Drugs2004; 64: 1547–1573.
67.
67 Glick SD Rossman K Steindorf S Maisonneuve IM Carlson M . Effects and aftereffects of ibogaine on morphine self-administration in rats.Eur J Pharmacol1991; 195: 341–345.
68.
68 Dzoljic ED Kaplan CD Dzoljic MR . Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats.Arch Int Pharmacodyn Ther1988; 294: 64–70.
69.
69 Glick SD Gallagher CA Hough LB Rossman KL Maisonneuve IM . Differential effects of ibogaine pretreatment on brain levels of morphine and (+)-amphetamine.Brain Res1992; 588: 173–176.
70.
70 Cappendijk SL Dzoljic MR . Inhibitory effects of ibogaine on cocaine self-administration in rats.Eur J Pharmacol1993; 241: 261–265.
71.
71 Sershen H Hashim A Lajtha A . Ibogaine reduces preference for cocaine consumption in C57BL/6By mice.Pharmacol Biochem Behav1994; 47: 13–19.
72.
72 Glick SD Kuehne ME Raucci J Wilson TE Larson D Keller RW . Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum.Brain Res1994; 657: 14–22.
73.
73 Dworkin SI Gleeson S Meloni D Koves TR Martin T . Effects of ibogaine on responding maintained by food, cocaine and heroin reinforcement in rats.Psychopharmacology1995; 117: 257–261.
74.
74 Glick SD Rossman K Rao NC Maisonneuve IM . Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor.Neuropharmacology1992; 31: 497–500.
75.
75 Aceto MD Bowman ER Harris LS May EL . Dependence studies on new compounds in the rhesus monkey, rat and mouse.NIDA Res Monogr1989; 95: 578–631.
76.
76 Aceto MD Bowman ER Harris LS May EL . Dependence studies of new compounds in the rhesus monkey and mouse.NIDA Res Monogr1990; 105: 640–681.
77.
77 Sharpe LG Jaffe JH . Ibogaine fails to reduce naloxone-precipitated withdrawal in the morphine-dependent rat.Neuroreport1990; 1: 17–19.
78.
78 Popik P Layer RT Fossom LH Benveniste M Geter-Douglass B Witkin JM . NMDA antagonist properties of the putative antiaddictive drug, ibogaine.J Pharmacol Exp Ther1995; 275: 753–760.
79.
79 Frances B Gout R Cros J Zajac JM . Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice.Fundam Clin Pharmacol1992; 6: 327–332.
80.
80 O'Hearn E Molliver ME . The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity.J Neurosci1997; 17: 8828–8841.
81.
81 Xu Z Chang LW Slikker W Ali SF Rountree RL Scallet AC . A dose–response study of ibogaine-induced neuropathology in the rat cerebellum.Toxicol Sci2000; 57: 95–101.
82.
82 Helsley S Dlugos CA Pentney RJ Rabin RA Winter JC . Effects of chronic ibogaine treatment on cerebellar Purkinje cells in the rat.Brain Res1997; 759: 306–308.
83.
83 Scallet AC Ye X Rountree R Nony P Ali SF . Ibogaine produces neurodegeneration in rat, but not mouse, cerebellum. Neurohistological biomarkers of Purkinje cell loss.Ann N Y Acad Sci1996; 801: 217–226.
84.
84 Glick SD Maisonneuve IM Szumlinski KK . Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener.Alkaloids Chem Biol2001; 56: 39–53.
85.
85 Binienda Z Beaudoin MA Thorn BT Prapurna DR Johnson JR Fogle CM . Alteration of electroencephalogram and monoamine concentrations in rat brain following ibogaine treatment.Ann N Y Acad Sci1998; 844: 265–273.
86.
86 Alper KR Lotsof HS Frenken GM Luciano DJ Bastiaans J . Treatment of acute opioid withdrawal with ibogaine.Am J Addict1999; 8: 234–242.
87.
87 Alper KR Lotsof HS Frenken GM Luciano DJ Bastiaans J . Ibogaine in acute opioid withdrawal. An open label case series.Ann N Y Acad Sci2000; 909: 257–259.
88.
88 Lotsof HS . Ibogaine in the treatment of chemical dependence disorders: Clinical Perspectives (A Preliminary Review). Multidisciplinary Association for Psychedelic Studies Bulletin; 1995; 5: 16–27.
89.
89 MDD-NIDA. Draft protocol: Rising Dose Tolerance Study using single administration to assess the safety and preliminary efficacy of ibogaine for the treatment of cocaine and/or heroin dependency.Rockville, Maryland: NIDA; 1993.
90.
90 Vastag B . Addiction treatment strives for legitimacy.Jama2002; 288: 9–101.
91.
91 Kontrimavičiūtė V Mathieu O Mathieu-Daudé JC Vainauskas P Casper T Baccino E . Distribution of ibogaine and noribogaine in a man following a poisoning involving root bark of the Tabernanthe iboga shrub.J Anal Toxicol2006; 30: 434–440.
92.
92 Best SE Olivieto AH Kosten TR . Opioid addiction – recent advances in detoxification and maintenance therapy.CNS Drugs1996; 6: 301–314.
93.
93 Lotsof HS; . Ibogaine in the treatment of chemical dependency disorders. Presented to the NIDA-Sponsored Ibogaine Review Meeting, Rockville, MD, March 1995.
94.
94 Mash DC Allen-Ferdinand K Mayor M Kovera CA Ayafore JF Williams IC . Ibogaine: Clinical observations of safety after single dose administrations. Problems of Drug Dependence 1998: Proceedings of the Sixtieth Annual Meeting. The College of Problems on Drug Dependence, Inc. NIDA Research Monograph, US Dept. of Health and Human Services, Bethesda, Maryland, 1999; 179: 294.
